# Foghorn lays off 40% of employees as Lilly cancer collab collapses over poor data

> **Open Intelligence Dossier** · First detected: 2026-10-02 12:00 UTC · Category: Business

## Executive Summary
Foghorn Therapeutics cuts 40% of staff after Eli Lilly ends a cancer collaboration due to poor data.

## Intelligence Brief
Recent coverage details significant operational and financial contractions at Foghorn Therapeutics, highlighted by a substantial reduction in workforce affecting forty percent of employees. According to reporting from outlets including Barron&amp;#039;s, Fierce Biotech, and qz.com, the layoffs coincide directly with the collapse of a cancer collaboration involving Eli Lilly. Additional reports from Investing.com, Seeking Alpha, and GuruFocus note that Eli Lilly ended the deal following poor data from a cancer program, specifically halting the FHD-909 program as indicated in a company update provided via GlobeNewswire. Financial institutions and market analysts have responded swiftly to the development, adjusting ratings and stock price targets across the board.


Coverage from TradingView shows that Guggenheim maintained a Buy rating with a five dollar price target, while H.C. Wainwright cut its stock price target to five dollars due to the program halt, as reported by Investing.com. Furthermore, TD Cowen downgraded Foghorn Therapeutics, changing its stock rating from a previous position to a Hold, specifically citing the trial halt and the Lilly exit in coverage tracked by Seeking Alpha and GuruFocus. The broader market context emphasizes intense trader focus on the company&amp;#039;s financial health, cash runway, and technical charts, as detailed by StocksToTrade.


The sudden termination of the major pharmaceutical partnership removes a primary catalyst and funding source for Foghorn Therapeutics, putting immediate pressure on the firm&amp;#039;s remaining strategic priorities and operational capacity. Coverage does not yet specify the exact timeline for the workforce reduction execution or the full financial impact of the partnership dissolution beyond the stated program halt and strategic updates. As the situation develops, market observers and stakeholders are tracking how the company manages its remaining cash runway and pivots its strategic priorities following the FHD-909 halt. Coverage from GlobeNewswire indicates that Foghorn Therapeutics has provided updates on these strategic shifts, but further details regarding pipeline adjustments or potential new partnerships remain to be seen in subsequent reporting from financial and biotech news sources.

## Multi-Source Evidence Table
| Source Outlet | Headline | Verification URL |
|---|---|---|
| GuruFocus | FHTX Downgraded by TD Cowen -- Rating Changed to Hold | [Source Link](https://news.google.com/rss/articles/CBMikwFBVV95cUxQS2FFbWUyU3RqZ2ZDUWduVzJUc3M5V19pbkdDV1NCLWZHd3Jnam9GdmVHSkhfRHdjbl9MbnEyMEZ4VDRNMXR5OGNqdTJuSWNKb3p4b1dxRHp3emxKMzhZdE42S0JBc0FXamlCUWJ5LUJwYjJpdllBOHpLX1RVVzhEeTRQNm1BUWgxZDQ5Y1lwbFZCUDQ?oc=5) |
| Seeking Alpha | Foghorn downgraded at TD Cowen on Lilly exit (FHTX:NASDAQ) | [Source Link](https://news.google.com/rss/articles/CBMiggFBVV95cUxOOUdLVzFtVzVkUVhLMHd3dG5xc2xjaGljaGRlb2x1SzBhUmNMeHhJeU5nQzVyLTZwRGlEWFpEbkFTRHlCczNmdk5YN29faGtRZ0ZzNnYyQXBDTzZLOFVWTFdFTmdLQ3BIbjMyMWV3SjhCdFlEbzFuMHFaVkItQ1kzSlRR?oc=5) |
| TradingView | Guggenheim maintains Buy rating on Foghorn Therapeutics, $5 price target | [Source Link](https://news.google.com/rss/articles/CBMizAFBVV95cUxNUGJSYWVKTXlMdmx0RllrRlZzcG00VEpUU3VPRnY0WlJyRV9nNmZvZ0VTaUhJRElUeFpRUFR1R0RCSE5jeVhlRDhUU0czYWhac18wX2o3bUU3ZVkzbmEtcnZDUkFaWjZKMlNVLWhFVkNXaWFwcDFjZUloV0x3aEh3UnVCaVRmWnVmTlVIYnN2WXJHSHpPOUdnOWNsdk1lNGx1M3k1YlNCV1ZZdTNpR1Q5ek0tekNUZVRKVWJEMVZMYkx4S1RWWV9OLUhSdDI?oc=5) |
| qz.com | Foghorn Therapeutics layoffs after Eli Lilly ends cancer deal | [Source Link](https://news.google.com/rss/articles/CBMihgFBVV95cUxPNm1Ld0NXNTdfUDRIZzN6Y2t4TzRHS2VtdnUwT05xcGdoYXVXa19WanhIdFctNlY1c2ZzaDdyN3lKbmdQdGZjN21nMFJobmdZcXhwdzd1V3h3X3pIUXIzeF9XLVlHOWRJeU9td3JGS0dIcUE4Ymc0bkJtOEU0VWVCSG5ET05OUQ?oc=5) |
| Investing.com | Foghorn Therapeutics stock price target cut to $5 by H.C. Wainwright on program halt | [Source Link](https://news.google.com/rss/articles/CBMi2AFBVV95cUxQVnFmU3NPUU5UX1Z2MVU4bFFybEJuUnA5cDRhM0FUQnpNWjJpVXJnSW1fZlNIVDhUdGhzSGxEZ3hzVnRGQU53eV9OQUVRMmxMbVdWMzNyZG9VX192UkNRR0xWNFZrQmFmZk9zbTRfbHFfR3l5eWVQUWd4aTNrcjJjeFFsRXZsaFhxaXY3TEFCOTlPQTE3MkxiSl9ORnlXQXBveVpTTE5XYmhLMFk0dDRkT1Bna2FvcnRIT2huSjc2OFFOdjhKWXEyNmJnU091Y3pyN2F5bExTZ2E?oc=5) |
| Investing.com | Foghorn Therapeutics stock rating cut to Hold by TD Cowen on trial halt | [Source Link](https://news.google.com/rss/articles/CBMiywFBVV95cUxQRFpBVnlRTC1BcnlGS2ZheWJxaHNrSFZ1VFE2bTNLSHFvUVkyOGZVQ2F1aTkyVXIwckRyRXRKc0g5NHhxNkRtcktwVERjMGtkX1FEUFNRNGx3SXNrM3BoWWh6QnVWRVVDdkoyZWZZdnI3ZE84U1ZuWTJGSDhYUEdzeGZJWEF4eVlMbXBuM2kyV3c3cmwxSjZ3NEZtakxDcGxCajBMOWxySjRiUmtoTWtPa1VHYmpwbW1UZTVnWEwwOXdiOFRJbmpyYmlsMA?oc=5) |
| StocksToTrade | FHTX Stock Slides As Traders Focus On Cash Runway And Charts | [Source Link](https://news.google.com/rss/articles/CBMigwFBVV95cUxPVmR4cEx6ZGpVQU4wUFcxdC00anV0N3Q4WGZCQ21hYVE5a1NYSWsxTjRQSjVMdjYxQmxLd3dXcTF1TnJGSUZvRF9hUlAzX1JPRFVDYVNzZ2dPSnJvWlRmcGtxeFhQQ0d2NktEZkZKVkx4V1pxWGhvMi1GY3F5WjF0dm0xRQ?oc=5) |
| Barron's | Foghorn Stock Sinks as Lilly Scraps Cancer Deal, Forcing 40% Layoffs | [Source Link](https://news.google.com/rss/articles/CBMilAFBVV95cUxPMmtKaElpWTdRMkRuV21XVG9GbXdkM0FuYk4xZkFCdU9wWDc3MEhIR2paQ3NsT2hFMU85UjJ5TWo0c1NmMU1lVWlkY0lodDlsTVJmNUZESzNBRXpueGFyVTZoZGZXbGZDR2h2RWozMlVRVGtGdFYwUncxWWYxVTNpRC0tNV9MUDR3MkNIbFNMTHBBZEJ2?oc=5) |
| GlobeNewswire | Foghorn Therapeutics Provides Update on FHD-909 and Strategic Priorities | [Source Link](https://news.google.com/rss/articles/CBMi3AFBVV95cUxOSDdjYkZIZ2UwZGoyRWU0aU50cXFKekpsR1VnUm5YSzhYVmJTdFdkMWpUdWVnS2FuQ3YtNm5iWXcyWGNrZ0dfdnBmbzBwVE52a0dvcGVtYWJjeGxDS0hFblRzeGFERkZnUmFVdi13a3V2amVDWVl3WUhjLUxlZG5vOHAyeG1OakNIcVZkZ1N5YjJtZHFaUTA1QkxFOWx2VXM3c2RRVmpXR0dCeENBRzc0TjdMd1NEV19YR3ZtWUtBYkc3YUpfRngtX1VyNDVhU0VOVHhRcW44M283anRD?oc=5) |
| Fierce Biotech | Foghorn lays off 40% of employees as Lilly cancer collab collapses over poor data | [Source Link](https://news.google.com/rss/articles/CBMiuAFBVV95cUxNQ2VNeHVEbnRtazV1SnE5bHFlVmVHak4tT2NUYVZuMDZnNWFLN2JfcF9BT25TUVBlUmdmM01DTFlfYW90NHUxUFZ2ZnhBYlM3N0lvdkhfbWlGUjFWZjZ6cl9nZ0YzQVcycHdBLWtRQlZKdzRBQm9VOTExb2FKWGtPTldERm1OR2xtZnF3VUJZdFVvek9FV0lZT05DeDdwOTF5TFlzaEwyMDhfblB1QVNjNFVyUlYzRkNJ?oc=5) |

---
*Canonical Source: https://pulse.byoaiapps.com/trend/2026-10-02/foghorn-lays-off-40-of-employees-as-lilly-cancer-collab-collapses-over-poor-data*
